Amgen "market perform," target price reduced

28.02.08 - Friedman,Billings,Ramsey &Co

NEW YORK, February 28 (newratings.com) - Analysts at Friedman Billings reiterate their "market perform" rating on Amgen Inc (AMGN). The target price has been reduced from $50 to $45.